First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS

Phase 1 Completed 77 enrolled Rockefeller University

RandomizedParallel-groupDouble-blindPrevention

Summary

This first clinical study of 10-1074-LS will evaluate its safety, tolerability and pharmacokinetics profile when administered alone or in combination with 3BNC117-LS to HIV (human immunodeficiency virus) -infected and HIV-uninfected individuals.

Timeline

Start: 2018-06-20
Primary completion: 2021-02-04
Completion: 2021-02-04

Publications

Valente PK, Wu Y, Cohen YZ, Caskey M, Meyers K. Behavioral and social science research to support development of educational materials for clinical trials of broadly neutralizing antibodies for HIV treatment and prevention. Clin Trials. 2021 Feb;18(1):17-27. doi: 10.1177/1740774520948042. Epub 2020 Aug 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Teropavimab	Monoclonal antibody	30 mg/kg	Subcutaneous
Subject	Teropavimab	Monoclonal antibody	150 mg	Subcutaneous
Subject	Teropavimab	Monoclonal antibody	200 mg	Subcutaneous
Subject	Teropavimab	Monoclonal antibody	225 mg	Subcutaneous
Subject	Teropavimab	Monoclonal antibody	240 mg	Subcutaneous
Subject	Teropavimab	Monoclonal antibody	250 mg	Subcutaneous
Subject	Teropavimab	Monoclonal antibody	300 mg	Subcutaneous
Subject	Zinlirvimab	Monoclonal antibody	3 mg/kg	Subcutaneous
Subject	Zinlirvimab	Monoclonal antibody	10 mg/kg	Subcutaneous
Subject	Zinlirvimab	Monoclonal antibody	30 mg/kg	Subcutaneous
Subject	Zinlirvimab	Monoclonal antibody	60 mg	Subcutaneous
Subject	Zinlirvimab	Monoclonal antibody	75 mg	Subcutaneous
Subject	Zinlirvimab	Monoclonal antibody	100 mg	Subcutaneous
Subject	Zinlirvimab	Monoclonal antibody	150 mg	Subcutaneous
Subject	Zinlirvimab	Monoclonal antibody	300 mg	Subcutaneous

First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS

Summary

Timeline

Publications

Drugs

Indications